Actuate Therapeutics, Common Stock Net Income
| ACTU Stock | 6.56 0.05 0.76% |
Actuate Therapeutics,'s fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Actuate Stock price.
| Last Reported | Projected for Next Year | ||
| Net Loss | -27.3 M | -28.6 M | |
| Net Loss | -27.3 M | -28.6 M | |
| Net Loss | (3.26) | (3.42) | |
| Net Income Per E B T | 0.90 | 0.80 |
Actuate Therapeutics, Common Company Net Income Analysis
Actuate Therapeutics,'s Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Actuate Therapeutics, Net Income | (27.29 M) |
Most of Actuate Therapeutics,'s fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Actuate Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Actuate Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Actuate Therapeutics, is extremely important. It helps to project a fair market value of Actuate Stock properly, considering its historical fundamentals such as Net Income. Since Actuate Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Actuate Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Actuate Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Actuate Therapeutics, Common reported net income of (27.29 Million). This is 107.99% lower than that of the Biotechnology sector and 138.95% lower than that of the Health Care industry. The net income for all United States stocks is 104.78% higher than that of the company.
Actuate Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Actuate Therapeutics,'s direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Actuate Therapeutics, could also be used in its relative valuation, which is a method of valuing Actuate Therapeutics, by comparing valuation metrics of similar companies.Actuate Therapeutics, is currently under evaluation in net income category among its peers.
Actuate Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Actuate Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Actuate Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Actuate Fundamentals
| Return On Asset | -3.49 | ||||
| Current Valuation | 160.19 M | ||||
| Shares Outstanding | 23.24 M | ||||
| Shares Owned By Insiders | 16.14 % | ||||
| Shares Owned By Institutions | 49.72 % | ||||
| Number Of Shares Shorted | 483.57 K | ||||
| Price To Book | 14.05 X | ||||
| EBITDA | (25.16 M) | ||||
| Net Income | (27.29 M) | ||||
| Total Debt | 404.99 K | ||||
| Book Value Per Share | (0.13) X | ||||
| Cash Flow From Operations | (21.84 M) | ||||
| Short Ratio | 7.32 X | ||||
| Earnings Per Share | (3.11) X | ||||
| Target Price | 26.75 | ||||
| Number Of Employees | 10 | ||||
| Market Capitalization | 136.67 M | ||||
| Total Asset | 9.32 M | ||||
| Retained Earnings | (132.38 M) | ||||
| Working Capital | 405.4 K | ||||
| Net Asset | 9.32 M |
About Actuate Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Actuate Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Actuate Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Actuate Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics,'s price analysis, check to measure Actuate Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics, is operating at the current time. Most of Actuate Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics,'s price. Additionally, you may evaluate how the addition of Actuate Therapeutics, to your portfolios can decrease your overall portfolio volatility.